Nephrogenic Diabetes Insipidus – Evidence‑Based Clinical Guideline

Clinical Presentation

• Infants and children who exhibit polyuria, polydipsia, failure to thrive, and hyper‑natraemic dehydration with urine osmolality < 200 mOsm/kg should raise suspicion for nephrogenic diabetes insipidus (NDI) 1, 2.
• The average age at diagnosis in the pediatric population is approximately 4 months 1.
• The classic triad in early life consists of polyuria, failure to thrive, and clinical signs of dehydration 1.
• Serum osmolality in affected infants is typically > 300 mOsm/kg due to hyper‑natraemia 1.
• Urine is inappropriately dilute (osmolality < 200 mOsm/kg, occasionally higher in milder disease) 1.
• Infants are especially vulnerable to severe dehydration because they cannot freely access fluids 1.
• Large oral fluid volumes may precipitate gastro‑oesophageal reflux and vomiting 3.

• Delayed diagnosis can lead to seizures, developmental delay, and cognitive impairment from prolonged hyper‑tonic dehydration 2, 4.

• In adults, the predominant presenting symptom is excessive thirst (polydipsia) 1, 5.

• Unexplained polyuria exceeding > 50 mL/kg per 24 h, accompanied by compensatory polydipsia, is characteristic 6.

• The combination of inappropriately dilute urine (urinary osmolality < 200 mOsm/kg) with high‑normal or elevated serum sodium is pathognomonic for diabetes insipidus (central or nephrogenic) 2, 4.

Diagnostic Approach

• Initial biochemical work‑up should include serum sodium, serum osmolality, and urine osmolality 6.
• A detailed family history and pedigree analysis are recommended to identify hereditary forms 2, 4.
• When diluted urine and elevated serum sodium are observed, early genetic testing is advised if nephrogenic DI is suspected 2.

Genetic Testing Strategy

• Approximately 90 % of NDI cases are X‑linked, caused by AVPR2 mutations on chromosome Xq28 and predominantly affect males 2, 4.
• Autosomal NDI accounts for < 10 % of cases, resulting from AQP2 mutations and affecting both sexes equally 2, 4.
• All symptomatic females should be tested for AVPR2 and AQP2 variants 6.
• Male offspring of known AVPR2‑mutation carriers should undergo genetic testing using umbilical‑cord blood immediately after birth 6.
• Testing should be performed in accredited laboratories using multigene panels that include copy‑number‑variant analysis 2.

Management

Dietary Management (First‑Line Foundation)

• Implement a low‑salt diet (≤ 6 g/day in adults; age‑appropriate limits in children) and restrict protein intake to < 1 g/kg/day in adults 8, 9.

9

• Provide age‑appropriate milk (not water) to ensure adequate caloric intake in infants 3.
• Space oral feeds and fluids to minimise vomiting from reflux 3.
• Consider nasogastric or gastrostomy tube feeding for children with recurrent vomiting, dehydration, or growth failure; 20‑30 % of pediatric NDI patients require tube feeding, rarely beyond age 4 years 3, 6.
• Ongoing support from an experienced dietitian is essential 3, 6.

Pharmacologic Management

• Symptomatic infants and children with NDI should receive thiazide diuretics combined with prostaglandin‑synthesis (COX) inhibitors 3, 6.

Thiazide Diuretics

• Mechanism: mild volume depletion increases proximal sodium and water reabsorption, reducing urine delivery to the collecting ducts 3, 6.
• Short‑term efficacy: up to 50 % reduction in urine output when paired with a low‑salt diet 3, 6.
• Typical dosing: hydrochlorothiazide 25 mg once or twice daily 9.
• Long‑term effect: a more moderate, sustained reduction in urine volume 3, 6.
• Add amiloride if thiazide‑induced hypokalaemia occurs 6.

COX Inhibitors

• Mechanism: enhance collecting‑duct water permeability by counteracting prostaglandin‑mediated inhibition 9, 6.
• Selective COX‑2 inhibitors (e.g., celecoxib) lower gastrointestinal bleeding risk compared with non‑selective agents 9.
• Discontinue COX inhibitors when patients reach adulthood (≥ 18 years) or earlier if continence is achieved, due to potential nephrotoxicity 8, 6.

• COX inhibitors are contraindicated during pregnancy 8.

• Initiation of drug therapy requires close monitoring of fluid balance, weight, and biochemical parameters because unchanged high fluid intake can precipitate marked hyponatraemia 3, 6.

Adult Considerations

• Treatment discontinuation becomes common with age (85 % treated in childhood vs 56 % in adulthood) 6.
• Continuation or cessation of diuretics should be guided by patient preference, balancing quality‑of‑life benefits against side‑effects 8, 6.
• Ongoing salt restriction enhances diuretic efficacy 9.

Emergency Management

• Every individual with NDI should possess an emergency plan that includes a diagnosis letter, intravenous‑fluid management instructions, specialist contact details, and a medical‑alert bracelet 8.

• For hyper‑natraemic dehydration, use 5 % dextrose (or 5 % glucose) solution for IV rehydration; isotonic saline is contraindicated 8.
• Calculate the initial infusion rate to avoid a serum sodium decline > 8 mmol/L per day 8.
• 5 % dextrose matches the low‑sodium urinary losses typical of NDI 10.
• Do not administer 5 % dextrose as a rapid bolus, to prevent abrupt sodium reduction 10.
• Isotonic fluids are reserved only for acute hypovolaemic shock, which is exceedingly rare in NDI 10.
• After isotonic resuscitation, provide free water to facilitate excretion of the renal osmotic load 10.

• Allow oral intake to thirst when feasible and resume oral feeding promptly 10.

• Monitoring during emergency care must include: neurological status, continuous fluid‑balance charting, serial body‑weight measurements, frequent serum electrolyte checks, and consideration of urinary catheter placement for accurate diuresis monitoring 8, 10.
• Management of hyper‑natraemic dehydration in NDI should be performed in specialised centres with disease expertise or under expert consultation 8.

Follow‑Up and Monitoring

Infants (0‑12 months)

• Clinical assessment (weight, height) every 2‑3 months 9.
• Laboratory panel (Na, K, Cl, HCO₃, creatinine/eGFR, uric acid) every 2‑3 months 9.
• Urine studies (osmolality, protein‑creatinine ratio, 24‑h volume) annually 9.
• Renal‑urinary ultrasound every 2 years to screen for hydronephrosis, bladder wall hypertrophy, and post‑void residual 9.

Children (>12 months)

• Clinical assessment every 3 months 9.
• Electrolytes and renal function every 3‑12 months 9.
• Annual urine osmolality and protein evaluation 9.
• Ultrasound at least every 2 years 9.

Adults

• Weight measurement annually 9.
• Complete metabolic panel and renal function annually 9.
• Comprehensive urine assessment annually 9.

• Ultrasound every 2‑3 years 9.

• Rationale: growth failure is a key early indicator, making height and weight critical in infancy 6.
• Approximately 50 % of adults with NDI develop chronic kidney disease stage ≥ 2, necessitating regular renal monitoring 6.
• Hydronephrosis occurs in about 34 % of patients and requires surveillance 9.

Special Considerations

• Peri‑operative and acute‑illness contexts demand vigilant fluid‑balance and electrolyte monitoring with specialist input 8.
• Genetic counselling is strongly recommended for affected individuals, heterozygotes, and at‑risk relatives after a confirmed molecular diagnosis and before pregnancy; counseling should cover inheritance patterns, recurrence risk, and reproductive options such as prenatal or pre‑implantation genetic testing 8.
• Hydronephrosis may be physiological; perform ultrasound with a full bladder to differentiate from pathological dilation 9.
• In roughly one‑third of patients, bladder dilatation resolves with double‑voiding, avoiding the need for urological intervention 8.